

Price: **315.6p**  
Market Cap: **£215.7m**  
Yield: **5.7%**

RIC/BLBG: PHP.L / PHP LN

(Current share price timed at 13.00pm  
21 March 2012)

#### Researchers

##### Colette Ord

+44 (0)20 7260 1290  
c.ord@numis.com

##### Charles Cade

+44 (0)20 7260 1327  
c.cade@numis.com

##### George Crowe

+44 (0)20 7260 1280  
g.crowe@numis.com

##### Ewan Lovett-Turner

+44 (0)20 7260 1299  
e.lovett-turner@numis.com

#### Sales

##### Chris Gook

+44 (0)20 7260 1378  
c.gook@numis.com

##### Tod Davis

+44 (0)20 7260 1381  
t.davis@numis.com

##### Katherine Miller

+44 (0)20 7260 1380  
k.miller@numis.com

##### James Glass

+44 (0)20 7260 1369  
j.glass@numis.com

Website: [www.numis.com/funds](http://www.numis.com/funds)

*\*Primary Health Properties is a corporate  
broking client of Numis Securities*

This marketing communication was  
prepared and approved by

**Numis Securities Ltd.**

The London Stock Exchange Building  
10 Paternoster Square

London EC4M 7LT, UK

Tel +44 (0) 20 7260 1000

Fax +44 (0) 20 7260 1010

Email mail@numis.com

## Primary Health Properties \*

### Asset-backed yield

Final results to 31 December 2011 highlighted solid growth in rental income, recurring profits, DPS and EPRA NAV. Moreover, the company secured £300m of debt in the year, largely removing near-term refinancing risk. Although rising debt costs have temporarily reduced dividend cover to c.77%, we believe that PHP can continue to grow dividends. We believe a return to full cover is possible by 2014 as the rent roll rises, perhaps sooner if the company completes more acquisitions. In our view, PHP offers a high quality, asset-backed dividend, generated from long-term government backed cash flow. With a prospective yield of 5.7%, we believe the shares remain attractive for income seekers.

- **Overview:** PHP listed in 1996 and converted to a REIT in 2007. The company seeks to generate rental income and capital growth from owning a portfolio of purpose-built, fully-let health care premises. Of the total rent roll, 90% comes from GPs and NHS occupiers who have their rents reimbursed by the government. This is a process which has been enshrined in law since 1948, and is a key driver of the investment case in our view. Since inception PHP has delivered annual shareholder returns of 12% including dividends of 178.25p; annual DPS has grown for 15 consecutive years.
- **Asset-backed income:** The portfolio comprises 161 assets with high visibility of cash flow resulting from long leases (average remaining term of 16.3 years) and a strong tenant covenant. The company is contracted to receive minimum lease payments of £526m (excl. rental growth), which we believe firmly underpins the portfolio value of £539.7m (inc commitments).
- **Defensive asset class:** Given the relative security of cash flows and positive rental growth drivers, property values have proven to be less volatile compared with commercial assets. Whilst this limits NAV upside from yield compression in a rising property investment market, the opposite is true in a falling market.
- **Improved financing position:** One year ahead of maturity, PHP has extended the average term of its debt to 5.6 years from 2.5 years, largely removing near term refinancing risk. Importantly, in our view, this was achieved without having to crystallise any significant mark to market losses from the interest rate swap portfolio, which carried an unrealised accounting loss of c.£49m at 31 December. Whilst the overall cost of debt has increased (230bps ave. margin from 70bps), we still anticipate further DPS growth. Our estimates assume that the higher finance costs are absorbed by growth in the rent roll from accretive acquisitions and positive rent reviews (+2.5% rental growth). PHP has c.£70m of firepower to add new stock to the portfolio in 2012. Encouragingly, the yield on new properties is currently 100-150bps higher than the combined finance and management cost.
- **Strong performance:** The attractive yield and defensive asset class have been key drivers of share price and property level outperformance versus the FTSE All-Share Real Estate and IPD All Property Indices over the past 1, 3 and 5 years.

For FSA purposes this marketing communication has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Important disclosures relating to Numis Securities Limited are on pages 10 to 11 and include the analyst certification on page 10. For investment banking relationships, if any, with companies mentioned in the report, potential conflicts of interest and additional disclosure please refer to pages 10 to 11. When applicable, disclosures regarding ratings may be found at <http://www.numiscorp.com/x/us/regulatory.html>

## Results Summary

### Solid operational performance

In the 12 months to 31 December, PHP delivered a solid operational performance reflecting the strong income characteristics and defensive nature of the property portfolio. Key highlights included:

- 3% rental growth

### Growing rent roll

Following successful lease reviews across the portfolio, average rental growth achieved was 3.0%. Combined with acquisitions and commitments this increased the annualised rent roll to £32.3m. The addition of eight properties during the year for £45.7m, added £2.9m of new rents and 18,996 square metres of fully let space. Looking forward, we believe annual growth of 2-3% is sustainable under the lease structure.

- 10% increase in recurring profits

### Strong recurring profit growth

Profit increased 10% to £10m. This excludes a £10m increase in property values but includes the expensing of arrangement fees on debt that has been refinanced.

- 15 consecutive years of DPS growth

PHP will pay a dividend of 9.25p on 5 April having gone ex-dividend on 7 March. We expect a similar payment in October 2012 resulting in an annualised DPS of 18.5p reflecting a prospective 5.7% yield.

- 2% increase in EPRA NAV

### Moderate EPRA NAV growth

Including commitments, the total portfolio was valued at £539.7m, incorporating a valuation uplift of £10.6m reflecting a positive shift in valuation yields to 5.74% from 5.79%. EPRA NAV increased 2% to 318.7p (311.5p 30 June), in line with our estimates. Basic NAV, which includes an unrealised mark to market impact of the interest rate swap portfolio, was 246.3p (275p as at 30 June).

- £300m of debt secured

### Extended average debt maturity

PHP secured £300m of debt including two new facilities and refinancing of £175m of existing loans which were due to mature in 2013. As at 31 December, borrowings totalled £303m. LTV was 57.8%, comfortably below the banking covenants which range between 65% and 70%.

### Balance sheet strengthened

The new lines of credit and refinancing have strengthened the balance sheet and should give investors comfort over the sustainability of dividends in our view. The weighted average maturity of debt has increased to 5.6 years from 2.5 years leaving PHP with a broad mix of lenders and a mixture of maturity dates.

### Most short-term debt now extended albeit at increased cost

**Table 1. Finance Facilities**

Provider	Maturity	Facility (£m)	Drawn (£m)	Headroom (£m)
RBS	Jan-13	5	0	5
AIB	Jan-13	30	30	0
Clydesdale	Jul-14	50	14.2	35.8
RBS/Santander	Mar-16	175	156.5	18.5
Aviva	Nov-18	75	75	0
Aviva	Dec-20	25	0	25
Aviva	Jan-32	27.3	27.3	0
<b>Total</b>		<b>387.3</b>	<b>303</b>	<b>84.3</b>

Source: Company Data

## Higher cost of debt reflected in estimates

## Refinance achieved without crystallising swap liability

## EPRA NAV is the key measure of portfolio performance

The next tranche of debt to mature is a £30m facility with AIB which is due for renewal in 2013. We understand that PHP has a number of options to replace this funding by either repaying it using headroom on its existing debt facilities, extend with the current lender or replace through a new lender.

Whilst the cost of group debt has increased (as expected) with average margins rising from 70 to 230 bps over Libor this is reflected in our estimates. The swap portfolio was a constraining factor in the debt negotiations although importantly management was able to extend its largest existing facility with RBS and Santander without incurring any swap break costs. Overall we believe the company achieved the best possible balance between maturity and cost.

Reflecting the long-term nature of its cash flows, PHP has built up a portfolio of interest rate swaps predominantly with RBS and AIB. These derivative contracts have a variety of expiry dates and will hedge interest rate exposure by fixing the cost of a maximum of c.£193m of its c.£300m debt at c.4.75%. Under IFRS accounting, these contracts must be marked to market. As the table below illustrates, money market rates are currently substantially below 4.75% creating a sizeable but unrealised liability on the balance sheet at the period end, in common with many other property companies.


**Table 2. Money Market Rates**

Instrument	Rate (%)	12 Mth Hi/Lo Rate (%)
5 Year Swap	1.76	3.0/1.4
10 Year Swap	2.63	3.9/2.2
5 Year Gilt Yield	1.25	1.7/0.9
10 Year Gilt Yield	2.44	3.9/2.0

Source: Bloomberg

As at 31 December, the mark to market valuation of the swap portfolio was £49.5m. While it reduced the basic NAV as at 31 December, as with other REITs we believe the key measure of portfolio performance is EPRA NAV. This strips out the impact of the swaps as these are likely to be held to maturity when their value will be zero. The mark to market value would only crystallise if PHP were to repay the related debt or cancel its swaps, we assume that neither scenario is likely in the near term. The chart below illustrates the NAV including and excluding the value of the swaps.

**Figure 1. EPRA NAV (p) and NAV incl. mark to market of swaps (p)**




Source: Company Data

PHP has a higher yield than commercial REITs and stronger dividend cover than MXF

## Attractive asset backed yield

The following chart looks at the yield from PHP relative to its closest healthcare peer and the broader commercial REITs sector.

**Figure 2. Peer Yield Comparison (%)**



Source: Numis Securities Investment Companies Research

The yield on PHP shares yield is higher than the commercial REIT peer group from a more defensive asset base in our view. While PHP's yield is lower than that of Medicx Fund (MXF), the closed-ended investment company, PHP has considerably higher dividend cover.

MXF currently targets a payment of 5.6p for 2012 (7.4% yield) which will cost c£13.7m in a full year, based on 245.35m shares in issue (before scrip) and following the recent share issue. Recurring net profit for the financial year to 30 September 2011 was £3.76m based on rent received of £11.7m. We expect this to rise to c£6m in the next 12-18 months as construction assets complete although this still leaves a sizeable shortfall to be paid out of capital.

As at 23 February 2012, the Medicx portfolio comprised 70 properties of which 61 are complete and nine are under construction. Rent received will rise to £17.1m once forward funded commitments complete over the next 12 months. However, assuming a full year of costs of £11.1m, we estimate that MXF needs to increase the rent roll 46% to c.£25m before it fully covers the dividend from recurring profits.

## PHP dividend growth to continue

PHP has delivered 15 consecutive years of dividend growth and we expect further DPS progression even after factoring in the recently increased cost of group debt. Our estimates assume a prospective yield of 5.7% which remains highly attractive in the current low interest rate environment.

**Table 3. Numis DPS Estimates**

	DPS	Growth (%)	Div cover (%)
2012F	18.5	3	77
2013F	19.0	3	82

Source: Numis Securities Investment Companies Research

PHP has delivered 15 consecutive years of DPS growth


3% DPS growth in 2012 and 2013

We anticipate 3% DPS growth in 2012 and 2013 albeit resulting in a lower level of dividend cover than has been the case in recent years. However, we believe that cover will be restored in the relatively short-term as higher finance costs are absorbed by growth in the rent roll from accretive acquisitions and positive rent reviews (+2.5% rental growth).

## Predictable increases in rental income

We believe PHP needs to generate c.£38.5m of rental income to pay a fully covered dividend. The following charts illustrate that this is achievable from existing resources. The following chart illustrates the potential incremental cash flows in the event that rents increase in line with the long-term trend range of between 2.5% or 3.5% per annum at rent review.


**Figure 3. Potential Incremental Income on Rent Reviews**



Source: Company Data

Factoring in rental growth at the lower end of this range at 2.5% pa would add £2.2m of incremental income by 2014. If rental growth were 3.5% this would add £3.14m. In addition, assuming PHP uses c£50m of its firepower to add new stock to the portfolio this could add a further £3m of rent assuming current market yields. Encouragingly, the yield on new properties is currently 100-150bps higher than total finance and management costs making each new purchase accretive to EPS.

**Figure 4. Rental income by 2014 (£m)**



Source: Numis Securities Research Department

## Portfolio Summary

**Ave unexpired lease term of 16.3 years**


**Asset management potential from shorter leases**

### Long lease length

The average unexpired lease length of the portfolio is 16.3 years, which coupled with regular upward-only rent reviews, results in high visibility of cash flow, particularly compared with commercial real estate operators. PHP can expect to receive minimum future lease payments of at least £526m from its existing asset base excluding any future rental growth. This bodes well for future dividend payments and underpins the valuation of the portfolio in our view.

Where leases are shorter than average, management undertakes asset management initiatives to enhance longevity of income. The team undertake between 5-10 projects per annum. Initiatives during 2011 included enhancements to eight sites which added rent of £82,000, generating a 35% valuation uplift on cost.

**Figure 5. PHP Lease Lengths**




Source: Company Data

In stark contrast to PHP's portfolio, commercial property lease lengths have been falling for the past decade, and are now just over five years on average. Many are subject to break clauses and long rent-free periods. Moreover, the outlook for rental growth remains muted in all but a few pockets of the market. According to the British Property Foundation/IPD Annual Lease Review, 63% of new commercial leases signed in 2010/11 were for five years or less. The proportion of commercial leases with a break clause increased to 31.1% from 29.4% in 2009/10. Overall, commercial rent free periods increased to 13.4 months.

### Strong covenant

Another comfort factor for dividends is the strength of the covenant. Of the total income, 90% is paid either directly or indirectly by the UK government.

**Figure 6. Covenant Strength**


Source: Company Data

### Government reimburses GP rent costs

In the case of GP tenants, the typical payment structure is quarterly. The most common lease in the portfolio provides that the relevant government body (NHS or PCT) pays GPs the current market rent for their premises, plus an allowance of 5% for any repairs. In turn, GPs pay the current market rent to PHP and accept responsibility for all repairs and maintenance.

### Pharmacy operators pay higher rents

Nine per cent of rents come from pharmacy operators including national players such as Lloyds, Rowlands and Boots. Their premises are usually next to GP surgeries, have co-terminus leases and command a higher rent per sq ft.

**Table 4. Portfolio Rental Levels**

Tenant	Area (sq m)	Area (sq ft)	Rent (£psm)	Rent (£psf)
NHS	160,842	1,721,009	175	16.17
Pharmacy	9,685	104,211	278	25.84
Other	3,910	42,072	110	10.22
Total	153,564	1,652,984	178	16.57

Source: Company Data

### Regular, upward only rent reviews

GP rents are subject to triennial reviews which provide potential to increase revenue on a regular basis

### 11.53% index linked

#### Inflation Protected Revenues

The regular rent review process provides an element of inflation protection as 11.53% of total rent roll is index linked with a floor at 0%: 1.89% is subject to a fixed uplift, typically increasing 2-3% pa every three years.

### Higher replacement costs will drive rental growth

The balance is subject to effective upwards only open market reviews, agreed with the District Valuers Office, a government agency. Key inputs into deciding a fair rent include the replacement cost of the asset, as well as general inflation and market evidence. In particular, replacement costs continue to rise, driven by tighter building regulation, higher specification requirements and increasing raw material prices. This should support rental growth across the portfolio.

Valuation yields less volatile than commercial property assets

Valuation yield to remain stable

## Lower Volatility of Asset Values

Lambert Smith Hampton values PHPs portfolio every six months based on the individual value of each property. Given the favourable income characteristics, strong covenants and generally matched supply and demand of primary care assets, valuation yields have been less volatile compared with other commercial real estate assets. The following table illustrates the significant difference in yield shift over the past five years between the property sub-sectors.

**Table 5. Yield Shift - Peak to Current**

	PHP	Prime Retail	Prime Industrial	Prime Office
Valuation yield at cycle peak (%)	5.2	4.3	5.3	4.5
Valuation yield at cycle low (%)	6.2	7.6	8.7	8.2
Movement	100 bps	330 bps	340 bps	370 bps
5 Year average (%)	5.7	5.6	6.5	5.9

Source: Company Data/Numis Securities Investment Companies Research/ IPD

Looking forward, we expect the overall valuation yield on the portfolio to remain stable.

## Growth Potential

The sector continues to benefit from a number of positive demographic and political drivers including an ageing population and cross-party commitment to the NHS. The market place for primary health assets in the UK is substantial, comprising 10,400 surgeries, 3,000 of which need to be replaced or substantially modified.

Putting this in context, PHP's portfolio comprises 161 assets. Providing access to funding remains available, we believe that PHP can continue to increase its market share. In particular, management believe the company is well positioned to benefit from the next phase of primary care premises development which should follow the passing of the Health and Social Care bill.



## Financial Summary

**Table 6. Income Summary**

	Dec 2010	Dec 2011	Dec 2012F	Dec 2013F
Rent & Related Income (£m)	26.9	30.7	34.2	36.3
Admin Costs (£m)	(6.1)	(5.5)	(5.5)	(5.5)
Net Finance Costs (£m)	(12.6)	(15.4)	(19.0)	(20.2)
Recurring Profit/Loss Before Tax (£m)	8.2	9.8	9.7	10.6
EPS (p)	12.4	14.3	14.2	15.5
DPS (p)	17.5	18.0	18.5	19.0
Shares in issue (m)	62.6	68.2	68.2	68.2
Divi Cost (£m)	10.95	12.2	12.6	12.9

Source Numis Securities Investment Companies Research

**Table 7. Balance Sheet Summary**

	Dec 2010	Dec 2011A	Dec 2012F	Dec 2013F
Property (£m)	472.7	528.7	576.7	606.7
Total Assets (£m)	476.3	531.4	579.4	609.4
Debt (£m)	(264.4)	(300.7)	(346.7)	(366.7)
Total Liabilities (£m)	(311.5)	(363.3)	(409.3)	(429.2)
Net assets (£m)	164.8	168.1	170.2	180.2
NAV p	262	247	250	264
EPRA NAV (£m)	195.6	217.6	223.6	231.7
EPRA NAV p	311.5	319.0	322	337
LTV %	56	57	60	60

Source Numis Securities Investment Companies Research

The following disclosures are addressed to US-based recipients.

## Analyst Certification

The research analyst who prepared this research report was Colette Ord. The analyst hereby certifies that all of the views expressed herein accurately reflect the analyst's personal views about any and all of the subject securities and/or issuers at the date of original publication of this document. The research analyst who prepared this research report also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the analyst in the research report.

## Important Disclosure

This research report has been prepared and approved by Numis Securities Limited ("Numis"), a securities dealer in the United Kingdom. Numis is not a registered broker-dealer in the United States and therefore is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided in the United States for distribution solely to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended. Any recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Numis Securities Inc. ("Numis Inc."). Numis Inc. may be contacted in writing or by phone: Numis Securities Inc., 275 Madison Avenue, 40<sup>th</sup> Floor, New York, NY 10016, U.S. phone (212) 277 7300. Numis Inc. is an affiliate of Numis. Under no circumstances should any recipient effect any transaction to buy or sell securities or related financial instruments through Numis.

Numis Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

Numis, Numis Inc. and/or their affiliates, directors, officers, and employees may have or have had interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the subject companies mentioned or referred to in this report.

The research analysts who prepared this research report receive compensation based upon various factors (such as the general perception of the analysts' ability and commitment to his/her analytical work) and upon the overall revenues including the investment banking revenues of Numis and/or one or more of its affiliates.

Primary Health Properties has been during the 12-month period preceding the date of this research report, a client of Numis.

Numis and/or one or more of its affiliates has received compensation for investment banking services from Primary Health Properties in the past 12 months.

Numis and/or one or more of its affiliates has managed or co-managed a public offering for Primary Health Properties in the past 12 Months.

Numis and/or one or more of its affiliates may receive or may seek to receive compensation for investment banking services from Primary Health Properties in the next 3 months.

## Market Making

As at the date of this research report, Numis and/or one or more of its affiliates is making a market in Primary Health Properties and Medicx Fund,

## Additional Disclosure

This Numis Securities Limited ("Numis") research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation, or particular needs of any specific recipient, even if sent only to a single recipient. This research report is offered solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell securities or related financial instruments, nor is it to be construed as a recommendation for Numis to effect any transaction to buy or sell securities or related financial instruments on behalf of any recipient. This report does not take into account the tax, or any other financial issues of investing in an Investment Company. You should seek independent professional advice on such matters. There is no express or implied understanding between Numis or Numis Securities Inc. ("Numis Inc.") and any recipient of this research report that Numis will receive any commission income in connection with this research report. The securities that may be described in this research report may not be eligible for sale in all jurisdictions or to certain categories of investors. This research report is based on information believed to be reliable, but it has not been independently verified and is not guaranteed as being accurate. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report.

Any statements or opinions expressed in this research report are subject to change without notice and Numis is not under any obligation to update or keep current the information contained herein. All statements and opinions expressed in this research report are made as of the date of this research report and are not held out as applicable thereafter. Neither Numis nor any of its directors, officers, employees, or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication; provided that this shall not exclude liability to the extent that this is impermissible under the law relating to UK financial services.

Numis may rely on information barriers, such as "Chinese Walls", to control the flow of information within the areas, units, divisions, groups, or affiliates of Numis.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the regulation of the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign corporations are typically not subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

Past performance is not an indication or guarantee of future performance and no representation or warranty, express or implied, is made by Numis with respect to future performance. The value of any investment or income from any securities or related financial instruments discussed in this research report is subject to volatility and can fall as well as rise. Investors may not get back the full amount they originally invested. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from any securities or related financial instruments discussed in this research report.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of Numis and Numis accepts no liability whatsoever for the actions of third parties in this respect

The following disclosures are addressed to non-US-based recipients.

### Regulatory Notice & Disclaimer

Numis regards this document as a marketing communication. It has been approved under part IV article 19 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") by Numis Securities Limited ("Numis") for communication in the United Kingdom only to investment professionals as that term is defined in article 19(5) of the FPO. Its contents are not directed at, may not be suitable for and should not be relied on by anyone who is not an investment professional including retail clients. Numis does not provide investment advisory services to retail clients. This marketing communication is not directed at you if Numis is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. You should satisfy yourself before reading it that Numis is permitted to provide marketing material concerning investments to you under relevant legislation and regulations.

This marketing communication is not an offer or a solicitation to buy or sell any security. It does not constitute a personal recommendation and recipients must satisfy themselves that any dealing is appropriate in the light of their own understanding, appraisal of risk and reward, objectives, experience, and financial and operational resources. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Non independent research is not subject under the Markets in Financial Instruments Directive ("MiFID") to any prohibition on dealing ahead of the dissemination of investment research. However, Numis is required by the FSA to have policies in place to manage the conflicts of interest which may arise in its production, which include preventing dealing ahead.

The prices of the investments referred to in this marketing communication and the income from them may go down as well as up and investors may realise losses on them. Neither past performance nor forecasts are a reliable indicator of future results. Numis accepts no fiduciary duties to the reader of this marketing communication and in communicating it Numis is not acting in a fiduciary capacity. Neither Numis nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error, inaccuracy or incompleteness of fact or opinion in it or lack of care in its preparation or publication except where such is caused by its gross negligence, wilful default or fraud; nor shall it exclude or restrict any liability it has under the regulatory system to the extent that to do so is impermissible under the law relating to financial services.

All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. Marketing communications will carry the date of publication or, on a marketing communication printed overnight, the date on which it was sent to the printers. Where a price is quoted in a marketing communications it will generally, in the absence of contrary words, be the latest practicable price prior to distribution or, in the case of a marketing communication printed overnight, the closing price at the close of business. Unless otherwise stated, prices in this marketing communication are derived from quotations on the London Stock Exchange.

A list of significant items which could create a conflict of interest and other material interests in relation to marketing communications, together with Numis's policy for managing such conflicts of interest, is set out on the Numis website ([www.numiscorp.com/x/regulatory.html](http://www.numiscorp.com/x/regulatory.html)).

Numis or one or more of its associates or a director or an employee of Numis or of an associate may from time to time have a position, or may have undertaken or may undertake an own-account transaction, in a security referred to in this document or in a related security. Such a position or such a transaction may relate to the market making activities of Numis or to other activities of Numis.

Numis or one or more of its associates may from time to time have a broking, advisory or other relationship with a company which is the subject of or referred to in this marketing communication, including acting as that company's official or sponsoring broker and providing corporate finance or other financial services. It is the policy of Numis to seek to act as corporate adviser or broker to many of the companies which are covered by the Research Department. Accordingly companies covered in any marketing communication may be the subject of marketing initiatives by the Corporate Finance Department.

A company covered in this marketing communication may have paid for an analyst's reasonable expenses to visit their premises or offered modest hospitality or entertainment; further details are available on request.

Printed marketing communications will identify material sources; electronic marketing communications are normally based on company announcements made through the Regulatory Information Service. In those cases (but not otherwise) where the subject company has seen a draft of the marketing communication and has suggested factual amendments which are incorporated by the researcher, this will be noted on the marketing communication. This applies normally only to printed pieces.

In printed marketing communications the risk warnings (if any) attaching to a particular company will be set out; in electronic pieces there is a cross-reference to the archive of marketing communications on the Numis website where, under the appropriate company name, details of such matters can be viewed.

The archive of marketing communications (available to all clients who normally receive Numis marketing communications) is available on the Numis website ([www.numiscorp.com/x/Mainresearch.html](http://www.numiscorp.com/x/Mainresearch.html)).

Numis accepts no responsibility whatever for any failure by a person resident outside the United Kingdom to observe the foregoing. No part of the content of any marketing communication may be copied, forwarded or duplicated in any form or by any means without the prior consent of Numis and Numis accepts no liability whatsoever for the actions of third parties in this respect.